

# CITATION REPORT

List of articles citing

## Prevalence of adverse events to radiopharmaceuticals from 2007 to 2011

DOI: 10.2967/jnumed.114.138057

Journal of Nuclear Medicine, 2014, 55, 1308-10.

**Source:** <https://exaly.com/paper-pdf/59287932/citation-report.pdf>

**Version:** 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
22	Local Treatment of Inflammatory Joint Diseases. <b>2015</b> ,		2
21	Pitfalls and Limitations of SPECT, PET, and Therapeutic Radiopharmaceuticals. <i>Seminars in Nuclear Medicine</i> , <b>2015</b> , 45, 470-8	5.4	12
20	Adverse reactions to radiopharmaceuticals in France: analysis of the national pharmacovigilance database. <i>Annals of Pharmacotherapy</i> , <b>2015</b> , 49, 39-47	2.9	12
19	Comparison of Tc-99m maraciclalide and Tc-99m sestamibi molecular breast imaging in patients with suspected breast cancer. <i>EJNMMI Research</i> , <b>2017</b> , 7, 5	3.6	10
18	Evaluation of Radiopharmaceutical Adverse Reaction Reports to the British Nuclear Medicine Society from 2007 to 2016. <i>Journal of Nuclear Medicine</i> , <b>2017</b> , 58, 2010-2012	8.9	7
17	Saving costs in cancer patient management through molecular imaging. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , <b>2017</b> , 44, 2153-2157	8.8	
16	Inhibition of viability of microorganisms in [F]-labeled radiopharmaceuticals. <i>Nuclear Medicine and Biology</i> , <b>2017</b> , 44, 105-113	2.1	1
15	American Society of Hematology 2018 guidelines for management of venous thromboembolism: venous thromboembolism in the context of pregnancy. <i>Blood Advances</i> , <b>2018</b> , 2, 3317-3359	7.8	188
14	Adverse Events of Diagnostic Radiopharmaceuticals: A Systematic Review. <i>Seminars in Nuclear Medicine</i> , <b>2019</b> , 49, 382-410	5.4	4
13	Radioactivity, Radionuclides, and Radiopharmaceuticals. <b>2019</b> , 1-18		3
12	Anaphylactic Reaction to Tc-99m Macrosalb. <i>Drug Safety - Case Reports</i> , <b>2019</b> , 6, 4	0.7	1
11	Patient-Reported Adverse Events of Radiopharmaceuticals: Development and Validation of a Questionnaire. <i>Drug Safety</i> , <b>2020</b> , 43, 319-328	5.1	1
10	Patient-Reported Adverse Events of Radiopharmaceuticals: A Prospective Study of 1002 Patients. <i>Drug Safety</i> , <b>2021</b> , 44, 211-222	5.1	0
9	Review of Adverse Reactions Associated with the Use of Common Diagnostic Radiopharmaceuticals. <i>Indian Journal of Nuclear Medicine</i> , <b>2021</b> , 36, 163-167	0.4	1
8	Adverse reactions to radiopharmaceuticals: liver radiopharmaceuticals. <i>Nuclear Medicine Communications</i> , <b>2021</b> , 42, 352-359	1.6	
7	Safety of Medicines: Detection and Reporting Adverse Reactions. <b>2015</b> , 1-27		0
6	Adverse Reactions to Radioiodine 131I Therapy of Goiter in West African Tertiary Hospital. <i>Molecular Imaging and Radionuclide Therapy</i> , <b>2016</b> , 25, 128-133	0.8	3

- 5 Adverse Reactions to and Altered Biodistribution of Radiopharmaceuticals. **2018**, 385-388
- 4 Chapter 22: Adverse Reactions to Radiopharmaceuticals. **2020**,
- 3 Chapter 14: Quality Control of Radiopharmaceuticals. **2020**,
- 2 Chapter 12: Radiopharmaceutical Chemistry: PET Agents. **2020**,
- 1 Proceedings: PET Drugs: A Workshop on Inspections Management and Regulatory Considerations.. *Journal of Nuclear Medicine*, **2022**, 8.9 ○